Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806026 · ClinicalTrials.gov registry record · Phase 3
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 731
- Enrollment target
NCT00806026 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 731 participants.
The verdict
NCT00806026, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 731 participants
- Enrollment target
Study Summary
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
Interventions
- DRUG Pregabalin
- DRUG placebo and pregabalin
- DRUG pramipexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 731 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806026
The ClinicalTrials.gov registry entry for NCT00806026 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 731 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pregabalin is the first listed.
NCT00806026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806026 about?
NCT00806026 is a clinical study titled "Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients". This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
What is the current status of trial NCT00806026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 731 participants. The study started on 2008-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00806026?
The interventions under investigation include: Pregabalin (DRUG), placebo and pregabalin (DRUG), pramipexol (DRUG).
Who is sponsoring clinical trial NCT00806026?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.